Oral poly(lactide-co-glycolide) nanoparticle based antituberculosis drug delivery: Toxicological and chemotherapeutic implications

Indian Journal of Experimental Biology

Volumn 44, Issue 6, 2006, Pages 459-467

  Pandey, Rajesh ^a   Sharma, Sadhna ^a   Khuller, G K ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Chemotherapy; Nanoparticles; Poly(lactide co glycolide); Toxicity; Tuberculosis

Indexed keywords

NANOMATERIAL; POLYGLACTIN; POLYMER; TUBERCULOSTATIC AGENT;

ANIMAL; ARTICLE; CHEMISTRY; DRUG DELIVERY SYSTEM; FEMALE; MALE; MOUSE; NANOTECHNOLOGY; ORAL DRUG ADMINISTRATION; RAT; TUBERCULOSIS; WISTAR RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTITUBERCULAR AGENTS; DRUG DELIVERY SYSTEMS; FEMALE; MALE; MICE; NANOSTRUCTURES; NANOTECHNOLOGY; POLYGLACTIN 910; POLYMERS; RATS; RATS, WISTAR; TUBERCULOSIS;

BACILLI (CLASS);

EID: 33745041084     PISSN: 00195189     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Jasmer R M, Seaman C B, Gonzalez L C, Kawamura L M, Ozmond D H & Daley C L, Directly observed therapy compared with self-administered therapy, Am J Respir Crit Care Med, 170 (2004) 561.
2. Mitchison D A, The diagnosis and therapy of tuberculosis during the past 100 years, Am J Respir Crit Care Med, 171 (2005) 699.
3. Pandey R, Zahoor A, Sharma S & Khuller G K, Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis, Tuberculosis (Edinburgh), 83 (2003) 373.
4. Sharma A, Pandey R, Sharma S & Khuller G K, Chemotherapeutic efficacy of poly (DL-lactide-coglycolide) nanoparticle encapsulated antitubercular drugs at sub-therapeutic dose against experimental tuberculosis, Int J Antimicrob Agents, 24 (2004) 599.
5. Pandey R, Sharma S & Khuller G K, Chemotherapeutic efficacy of nanoparticle encapsulated antitubercular drugs, Drug Deliv, (2005) (In Press).
6. Bala I, Hariharan S & Ravi Kumar M N V, PLGA nanoparticles in drug delivery: The state of the art, Crit Rev Ther Drug Carrier Syst, 21 (2004) 387.
7. Nuermberger E & Grosset J, Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections, Eur J Clin Microbiol Infect Dis, 23 (2004) 243.
8. Pandey R & Khuller G K, Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis, Tuberculosis (Edinburgh) 85 (2005) 227.
9. USP 24/NF 18, 2000, US Pharmacopoeial Convention, Rockville, MD, p 1645-1646.
10. Lalande V, Truffot-Pernot C, Paccaly-Moulin A, Grosset J & Ji B, Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice, Antimicrob Agents Chemother, 37 (1993) 407.
11. Lounis N, Truffot-Pernot C, Bentoucha A, Robert J, Ji B & Grosset J, Efficacies of clarithromycin regimens against Mycobacterium xenopi in mice, Antimicrob Agents Chemother, 45 (2001) 3229.
12. Pandey R & Khuller G K, Chemotherapeutic potential of alginate-chitosan microspheres as antitubercular drug carriers, J Antimicrob Chemother, 53 (2004) 635.
13. Lounis N, Maslo C, Truffot-Pernot C, Grosset J & Boelaert R J, Impact of iron loading on the activity of isoniazid or ethambutol in the treatment of murine tuberculosis, Int J Tuberc Lung Dis, 7 (2003) 575.
14. Grosset J, Lounis N, Truffot-Pernot C, O'Brien R J, Raviglione M C & Ji B, Once-weekly rifapentine-containing regimens for the treatment of tuberculosis, Am J Respir Crit Care Med, 157 (1998) 1436.
15. Moghimi S M, Hunter A C & Murray J C, Nanomedicine: current status and future prospects, FASEB J, 19 (2005) 311.
16. Mariappan T T, Jindal K C & Singh S, Overestimation of rifampicin during colorimetric analysis of antituberculosis products containing isoniazid due to formation of isonicotinyl hydrazone, J Pharm Biomed Anal, 36 (2004) 905.
17. Jain R, Shah N H, Malick A W, Rhodes C T. Controlled drug delivery by biodegradable poly (ester) devices: Different preparative approaches, Drug Dev Ind Pharm, 24 (1998) 703.
18. http://www.accessdata.fda.gov/scripts/cder/onctools/labels.cfm?GN= goserelin+acetate.
19. Louveau C, Descroix D, Garnier L, Delamanche I, Chavarot P, Ramisse F, Marchal G & Vergnaud G, A nose-only apparatus for airborne delivery of Mycobacterium tuberculosis to mice: calibration of biological parameters, Microbes Infect, 7 (2005) 457.
20. Johnson C M, Pandey R, Sharma S, Khuller G K, Basaraba R J, Ormes I M & Lenaerts A J, Oral therapy with poly (DL-lactide-co-glycolide) nanoparticle encapsulated antituberculosis drugs against Mycobacterium tuberculosis infected guinea pigs, Antimicrob Agents Chemother, 49 (2005) 4335.
21. Munoz-Elías E J, Timm J, Botha T, Chan W-T, Gomez J E & McKinney J D, Replication dynamics of Mycobacterium tuberculosis in chronically infected mice, Infect Immun, 73 (2005) 546.